Back to top
more

Amneal Pharmaceuticals (AMRX)

(Delayed Data from NSDQ)

$5.40 USD

5.40
1,317,983

+0.11 (1.98%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $5.41 +0.01 (0.19%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bausch (BHC) Starts Litigation Against Amneal for Xifaxan

by Zacks Equity Research

Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.

Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?

by Zacks Equity Research

Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 100% and 2.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Amneal (AMRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Amneal (AMRX) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

United Therapeutics (UTHR) delivered earnings and revenue surprises of 10.02% and 5.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amneal (AMRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Amneal (AMRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Amneal (AMRX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?

by Zacks Equity Research

Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.

Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Amneal (AMRX)

by Zacks Equity Research

Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Haemonetics (HAE) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Amneal (AMRX) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 90% and 6.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY

by Zacks Equity Research

Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.

Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug

by Zacks Equity Research

Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.

Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline

by Zacks Equity Research

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?